Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) EPS (diluted)
Gilead Sciences, Inc.'s EPS (diluted) for fiscal 2025 was $6.78, up 1,684.2% from $0.38 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$2.67. Over the past ten years it has ranged from $0.10 (fiscal 2020) to $11.91 (fiscal 2015); the current reading is higher than 82% of that period. Gilead Sciences, Inc. ranks 19th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $6.78 | 1,684.21% |
| FY2024 | $0.38 | (91.56%) |
| FY2023 | $4.50 | 23.63% |
| FY2022 | $3.64 | (26.17%) |
| FY2021 | $4.93 | 4,830.00% |
| FY2020 | $0.10 | (97.63%) |
| FY2019 | $4.22 | 1.20% |
| FY2018 | $4.17 | 18.80% |
| FY2017 | $3.51 | (64.69%) |
| FY2016 | $9.94 | (16.54%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$8.45 | — |
| Mar 2026 | $1.61 | (7.47%) |
| Dec 2025 | $1.74 | (28.40%) |
| Sep 2025 | $2.43 | 55.77% |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. compare | $16.09 |
| AZN AstraZeneca PLC compare | $6.69 |
| NVS Novartis AG compare | $6.63 |
| BMY Bristol Myers Squibb Company compare | $4.54 |
| NVO Novo Nordisk A/S compare | $4.09 |
| SNY Sanofi compare | $1.91 |
| MRK Merck & Co., Inc. compare | $1.25 |
| PFE Pfizer Inc. compare | $0.76 |
| GILD Gilead Sciences, Inc. | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on GILD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement